由阿克罗林诱导的PKM2修饰驱动NETosis和质瘤进展
Hsiang-Tsui Wang1, Zhen-Jie Tong2, Ya-Rou Lin2
1Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan; Institute of Food Safety and Health Risk Assessment, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan; Doctor Degree Program in Toxicology, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Free radical biology & medicine
|October 6, 2025
概括
一种与脑瘤相关的分子阿克罗莱因,驱动了在质母细胞瘤中中性粒细胞外细胞陷 (NET) 的形成. 抑制这种称为NETosis的过程,可能为侵袭性脑癌提供一种新的治疗策略.
科学领域:
- 神经瘤学神经瘤学
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
背景情况:
- 质母细胞瘤 (GBM) 是一种与缺氧和治疗耐药性相关的侵袭性脑瘤.
- 缺氧促进脂质过氧化,产生烯蛋白,导致细胞损伤和氧化应激.
- 通过NETosis释放的中性粒细胞外细胞陷 (NETs) 与瘤进展和预后不佳有关.
研究的目的:
- 为了研究阿克罗莱因在调节质瘤中NETosis中的作用.
- 阐明在质母细胞瘤中关联阿克罗莱因,PKM2和NETosis的分子机制.
- 评估针对阿克罗莱因-PKM2-NET轴的治疗策略.
主要方法:
- 从质瘤患者的外围中性粒细胞的转录组分析.
- 结核瘤细胞和中性粒细胞的体外共同培养系统.
- 在患者的血和瘤组织中分析阿克罗莱因和NET水平.
- 药理上抑制PKM2和阿克罗莱因清除.
- 在皮下和正管质瘤模型中评估瘤生长.
主要成果:
- 质瘤患者表现出高调节的NET相关途径和高的NET水平,与烯蛋白积累相关.
- 缺氧诱导的阿克罗莱因促进NETosis,增强质瘤细胞的增殖和迁移.
- 阿克罗林修改PKM2,诱导其核转位和HIF-1α的联合激活,导致IL-6和IL-8的表达增加.
- 激活PKM2 (TEPP-46) 和吸收阿克罗莱因 (海德拉) 在体外抑制了NETosis,并在体内抑制了瘤生长.
结论:
- 阿克罗莱因是质母细胞瘤中NETosis的关键调节者,形成了阿克罗莱因-PKM2-NET轴.
- 针对NETosis,可能通过烯蛋白清除或PKM2调制,代表了质母细胞瘤的一个有前途的治疗途径.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K


